MY149170A - Smoothened polypeptides and methods of use - Google Patents

Smoothened polypeptides and methods of use

Info

Publication number
MY149170A
MY149170A MYPI20091748A MYPI20091748A MY149170A MY 149170 A MY149170 A MY 149170A MY PI20091748 A MYPI20091748 A MY PI20091748A MY PI20091748 A MYPI20091748 A MY PI20091748A MY 149170 A MY149170 A MY 149170A
Authority
MY
Malaysia
Prior art keywords
functional fragment
inhibiting
functional
treating
methods
Prior art date
Application number
MYPI20091748A
Other languages
English (en)
Inventor
Tarasova Nadya
Dean Michael
Lou Hong
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Publication of MY149170A publication Critical patent/MY149170A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI20091748A 2006-10-31 2007-10-30 Smoothened polypeptides and methods of use MY149170A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85542206P 2006-10-31 2006-10-31

Publications (1)

Publication Number Publication Date
MY149170A true MY149170A (en) 2013-07-31

Family

ID=39492945

Family Applications (2)

Application Number Title Priority Date Filing Date
MYPI20091748A MY149170A (en) 2006-10-31 2007-10-30 Smoothened polypeptides and methods of use
MYPI2013000956A MY181496A (en) 2006-10-31 2007-10-30 Smoothened polypeptides and methods of use

Family Applications After (1)

Application Number Title Priority Date Filing Date
MYPI2013000956A MY181496A (en) 2006-10-31 2007-10-30 Smoothened polypeptides and methods of use

Country Status (13)

Country Link
US (3) US8198402B2 (enExample)
EP (2) EP2431388A1 (enExample)
JP (3) JP5399255B2 (enExample)
KR (1) KR101563010B1 (enExample)
CN (2) CN103435694A (enExample)
AU (1) AU2007329678A1 (enExample)
CA (1) CA2667821A1 (enExample)
MY (2) MY149170A (enExample)
NZ (1) NZ576467A (enExample)
PH (1) PH12013502425B1 (enExample)
SG (2) SG175691A1 (enExample)
WO (1) WO2008070357A2 (enExample)
ZA (1) ZA200902894B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG175691A1 (en) * 2006-10-31 2011-11-28 Us Gov Health & Human Serv Smoothened polypeptides and methods of use
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
JP2011522773A (ja) * 2007-12-27 2011-08-04 インフィニティ ファーマスーティカルズ、インク． 治療剤での癌の処置方法
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
WO2009086451A1 (en) 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
CA2769795C (en) 2009-08-05 2020-01-07 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
WO2011088404A1 (en) * 2010-01-15 2011-07-21 Infinity Pharmaceuticals , Inc Treatment of fibrotic conditions using hedgehog inhibitors
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ， インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3238722B1 (en) 2011-01-10 2019-03-13 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20141371A1 (es) 2011-08-29 2014-10-13 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
EP2925363A4 (en) 2012-11-29 2016-11-09 Strasspharma Llc METHOD FOR MODULATING FOLLICLE-STIMULATING HORMONACTIVITY
NZ629037A (en) 2013-03-15 2017-04-28 Infinity Pharmaceuticals Inc Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
KR20160013204A (ko) 2013-05-30 2016-02-03 인피니티 파마슈티칼스, 인코포레이티드 Pi3 키나아제 동형단백질 조절제를 사용하는 암의 치료
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR101723649B1 (ko) 2014-10-23 2017-04-06 서울대학교산학협력단 신규한 펩티드 화합물, 이의 생산 방법, 및 이의 용도
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US20170231968A1 (en) 2016-02-11 2017-08-17 PellePharm, Inc. Method for relief of and treatment of pruritus
JP6889432B2 (ja) * 2016-04-28 2021-06-18 学校法人甲南学園 樹脂固定ペプチド
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies
CN110520144B (zh) * 2017-02-19 2024-04-05 本-古里安大学B.G.内盖夫技术和应用公司 肽激酶抑制剂及其使用方法
CN108644311B (zh) * 2018-05-22 2019-09-06 东北大学 一种基于硬化立方刚度吸振器实现方法及吸振器
EP4185279A4 (en) 2020-07-24 2024-05-01 Secura Bio, Inc. TREATING CANCER WITH PI3-KINASE ISOFORM MODULATORS

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
IN165717B (enExample) 1986-08-07 1989-12-23 Battelle Memorial Institute
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
AU8380898A (en) * 1997-07-01 1999-01-25 Ingham, Philip W Vertebrate smoothened gene, gene products, and uses related thereto
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
US6683192B2 (en) * 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
WO2001081408A2 (en) * 2000-04-21 2001-11-01 New England Medical Center G-protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same
BR0117063A (pt) * 2001-07-02 2004-07-27 Sinan Tas Uso de ciclopamina no tratamento de carcinoma de células basais e outros tumores
EA007339B1 (ru) * 2001-07-27 2006-08-25 Кьюэрис, Инк. Медиаторы путей передачи сигналов генами hedgehog, содержащие их композиции и способы применения указанных веществ
EP1634083A2 (en) * 2003-06-17 2006-03-15 VIB vzw Peptide combos and their uses
US8440627B2 (en) * 2004-11-04 2013-05-14 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of use
US8088976B2 (en) * 2005-02-24 2012-01-03 Monsanto Technology Llc Methods for genetic control of plant pest infestation and compositions thereof
US20070266449A1 (en) * 2006-05-12 2007-11-15 Zivin Robert A Generation of animal models
SG175691A1 (en) * 2006-10-31 2011-11-28 Us Gov Health & Human Serv Smoothened polypeptides and methods of use

Also Published As

Publication number Publication date
CA2667821A1 (en) 2008-06-12
SG178743A1 (en) 2012-03-29
WO2008070357A9 (en) 2008-08-14
US20100093625A1 (en) 2010-04-15
PH12013502425A1 (en) 2014-10-27
WO2008070357A2 (en) 2008-06-12
JP5399255B2 (ja) 2014-01-29
PH12013502425B1 (en) 2014-10-27
JP2013255500A (ja) 2013-12-26
US8198402B2 (en) 2012-06-12
EP2431388A1 (en) 2012-03-21
EP2078036A2 (en) 2009-07-15
JP2015180630A (ja) 2015-10-15
US20130316957A1 (en) 2013-11-28
MY181496A (en) 2020-12-23
CN103435694A (zh) 2013-12-11
JP2010508305A (ja) 2010-03-18
US20120282196A1 (en) 2012-11-08
NZ576467A (en) 2012-03-30
AU2007329678A1 (en) 2008-06-12
US8546524B2 (en) 2013-10-01
KR20090084839A (ko) 2009-08-05
CN101616931A (zh) 2009-12-30
KR101563010B1 (ko) 2015-10-26
SG175691A1 (en) 2011-11-28
HK1137031A1 (en) 2010-07-16
JP5739484B2 (ja) 2015-06-24
CN101616931B (zh) 2013-08-21
WO2008070357A3 (en) 2009-02-26
ZA200902894B (en) 2010-04-28

Similar Documents

Publication Publication Date Title
PH12013502425B1 (en) Smoothened polypeptides and methods of use
KR102694658B1 (ko) 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
NZ587105A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
CY1121132T1 (el) ΠΛΗΡΩΣ-ΑΝΘΡΩΠΙΝΑ ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ANTI-vap-1
MX2024005678A (es) Receptores de celulas t que reconocen p53 mutado.
IN2012DN03368A (enExample)
MX2022010175A (es) Proteinas de union a flt3 y metodos de uso.
ATE466085T1 (de) Protease-resistente modifizierte interferon alpha polypeptide
CY1114944T1 (el) Σταθεροποιημενα αλφα ελικοειδη πεπτιδια και χρησεις αυτων
MX2021015877A (es) Receptores de celulas t que reconocen la mutacion r175h o y220c en p53.
WO2020186207A8 (en) Non-viral dna vectors and uses thereof for expressing fviii therapeutics
BRPI0816405B8 (pt) complexos de rna e pepitídeos catiônicos para transfecção e para imunoestimulação
NZ599792A (en) Immunomodulatory polypeptides derived from il- 2 and their use thereof in the therapeutic of cancer and chronic infections
ATE482972T1 (de) Tgf-beta1-bindende und geträgerte peptide
WO2011036443A9 (en) S1 protease c- terminal polypeptides and uses thereof for treating inflammation or coagulation disorders
DE602004018141D1 (de) Polypeptide mit bindungsaffinität für her2
Ilyaskin et al. Inhibition of the epithelial sodium channel (ENaC) by connexin 30 involves stimulation of clathrin-mediated endocytosis
WO2008040190A8 (fr) Petits peptides pour anti-angiogenèse et utilisation de ceux-ci
ATE473283T1 (de) Dna-expressionsvektoren
DK1144600T3 (da) Akt-3-nukleinsyre, polypeptider og anvendelser deraf
MX2025007855A (es) Proteina triespecifica dirigida a trop2 para el tratamiento del cancer
WO2010117997A3 (en) Peptide targeting of inner ear cells
ATE480552T1 (de) Stq-peptide
SE0301987D0 (sv) New polypeptide
WO2005123760A3 (en) Treating cancer